



# **Gynecologic Cancer in Women with Lynch Syndrome**

**Sarah E. Ferguson, MD FRCSC**

**Division of Gynecologic Oncology, Princess  
Margaret Hospital, University of Toronto**

**June 11, 2013**

# **Objective**

- 1. To review the life-time risk of gynecologic cancer**
- 2. To review potential symptoms of gynecologic cancer**
- 3. To discuss data and controversies of screening for gynecologic cancer**
- 4. To discuss data on risk-reducing surgery**

# Lynch Syndrome

- **Lynch Syndrome (LS) is an inherited cancer susceptibility syndrome**
- **Characterized by familial clustering of cancers (e.g. colorectal, endometrial)**
- **Autosomal dominant genetic defects in mismatch repair genes (MMR)**
  - ***MLH1, MSH2, MSH6, PMS2***
- **3-5% of unselected women with EC have LS<sup>1,2</sup>**

<sup>1</sup>Ferguson SE ASCO, 2013 <sup>2</sup>Hampel H. *et al. Cancer Res* 2007;

# LS–Associated Lifetime Risk of Cancer

Cancer	General Population Risk	Lynch Syndrome	<i>MLH1</i> and <i>MSH2</i>	<i>MSH6</i>	<i>PMS2</i>
Colon	6%	40-50%	40-80%	10-22%	15-20%
Endometrium	2.7%	30-60%	25-60 %	16-26%	15%
Ovary	1.7%	12%	4-24%	1-11%	-

# Endometrial Cancer and LS

**Stage IA Endometrial Cancer**



**Stage IB Endometrial Cancer**



# Endometrial Cancer and LS

- **EC is often the first cancer or “sentinel” cancer in LS<sup>1</sup>**
- **Significant lead time before 2<sup>nd</sup> cancer**
- **Opportunity to impact patient and family members with CRC screening and risk-reducing surgery<sup>2,3</sup>**
- **Difficult to identify women with EC at risk for LS:**
  - **Criteria for LS colorectal-based**
  - **Dependence on detailed family history**
  - **2/3 with EC would not be identified<sup>4,5</sup>**


<sup>1</sup>Lu *et al. Obstet Gynecol*, 2005, <sup>2</sup>Jarvinen *et al Gastroenterology* 1995; <sup>3</sup>Schmeler *et al. NEJM* 2006; <sup>4</sup>Ferguson SE ASCO, 2013  
<sup>5</sup>Hampel H. *et al. Cancer Res* 2007;.

# **Endometrial Cancer and LS**

- **Median age of developing EC significantly younger**
  - median age late 40's compared to age 63
- **Similar types of endometrial cancer as in sporadic EC**
  - 20% high risk type of cancer; may require chemotherapy or radiation
- **Similar stage distribution- 80% stage I**
- **Often associated with symptoms:**
  - Postmenopausal bleeding
  - Bleeding between periods
  - Heavy periods
  - Irregular periods

# Ovarian Cancer and LS

## Stage IIIC Cancer





# Ovarian Cancer and LS

- **Median age of developing OV is significantly younger than**
  - **median age early 40's compared to early 60's**
- **Unlike sporadic or other cancer syndromes, different type of ovarian cancer: endometrioid, clear cell type**
- **Different stage distribution- 80% stage I (70% stage III/IV for sporadic)**
- **Often picked up incidentally at surgery for EC**
- **May have better prognosis than sporadic OC likely due to early stage at diagnosis**
- **May have more predictable progression from early stage to advanced stage compared to sporadic or *BRCA* OC**

# Gynecologic Symptoms that Need Investigation


- **Endometrial**
  - Postmenopausal bleeding
  - Bleeding between periods
  - Heavy periods
  - Irregular periods
- **Ovarian** (symptoms almost daily for > 2-3 weeks)
  - Bloating
  - Pelvic or abdominal pain
  - Difficulty eating or feeling full quickly
  - Urinary symptoms (going often or having urgenc)
- These symptoms are non-specific and may be due to other non-cancer causes




# What Investigations Should be Performed for these Symptoms?

- **Abnormal or Postmenopausal Bleeding:**
  - **ENDOMETRIAL SAMPLE** (in office biopsy preferred or D&C if no delay)
  - **Ultrasound-** but should not delay sampling of endometrium
  - Sometimes need to advocate for yourself to get to MD that can do these tests
- **Bloating, abdominal/pelvic pain, difficulty eating or urinary symptoms:**
  - **ULTRASOUND-** to assess ovaries/pelvis/abdomen
  - +/- CA 125 depending on ultrasound results

# In Office Endometrial Biopsy



# Transvaginal Ultrasound



# **Screening for Gynecologic Cancer in Women with Lynch Syndrome**

- **Ideally want to find precancerous or very early cancerous lesions to minimize morbidity of treatment (requiring less extensive therapy) and decreasing mortality**
- **We have evidence that CRC screening in the general population and in individuals with LS decreases CRC-related deaths and morbidity (finding precancerous lesions)**

# **Screening for Endometrial Cancer**

- **There is an early precancerous lesion and a step wise development from precancer to cancer for most types of endometrial cancer**
- **Therefore there is potential that screening could find these early lesions and offer benefit by minimizing treatment and preventing advanced cancer diagnosis**

# **Screening for Endometrial Cancer**

- **There is an early precancerous lesion and a step wise development from precancer to cancer for most types of endometrial cancer**
- **Therefore there is potential that screening could find these early lesions and offer benefit by minimizing treatment and preventing advanced cancer diagnosis**



# Screening for Endometrial Cancer

- **No data on EC screening in the general population to guide us:**
  - **Low prevalence of disease**
  - **High rate of PMB as an early symptom resulting in early stage of diagnosis with excellent prognosis**
- **Minimal data in women with LS:**
  - **Average age of women with EC are premenopausal so abnormal bleeding symptoms not as reliable**
  - **Higher prevalence of disease**
  - **May have benefit in this population but very few studies**

# Screening for Endometrial Cancer

- **Only 2 prospective studies which looked at ultrasound with endometrial sampling:**
  - **Increased rate of precancer and cancer when endometrial sampling is added yearly**
  - **66-100% of these lesions would be missed if ultrasound used alone**
  - **No data on whether lives will be saved or if women will undergo less treatment by participating in EC screening**

# Screening for Ovarian Cancer

- Excellent evidence in the general population and in other high risk populations (*BRCA1/2* mutation carriers) that there is **No Benefit** of screening for OC with ultrasound and CA125
- Actual increase rate of complications secondary to investigating false positive test results
- These results likely due to the fact that:
  - Most present with advanced stage disease
  - No preclinical lesion identifiable with current screening methods

# Screening for Ovarian Cancer in Lynch Syndrome

- **Is OC a different disease in LS?**
  - Different histology
  - More present with early stage is there a longer preclinical stage
- **Could there be a benefit in this population?**
  - Lower prevalence of disease compared to BRCA1/2
  - Small # of women with LS
- **Significant rate of interval cancers which may give false sense of security**

# **Consensus Guidelines For Gynecologic Cancer Screening**

- **No evidence to support screening for EC however annual endometrial sampling is an option and often recommended**
- **May be circumstances where OC may be helpful but no evidence to support its benefit. Possible screening with transvaginal ultrasound and CA125**


# **What Can Be Done to Prevent Gynecologic Cancer?**

- **Study that compared women who had risk-reducing surgery (removal ovaries and uterus) to those women who had not had surgery**
- **No cases of gynecologic cancer in those that had surgery**
- **33% developed EC and 5% developed OC in the non-surgery group**
- **EC median age 46 years and OC median age 42 years**

# **Risk-Reducing Surgery**

- **Strong recommendation that women undergo risk-reducing surgery when completed child-bearing**
- **Removal of uterus and ovaries by age 40 b/c cancer risk significantly increases after age 40**
- **Difficult to give recommendations based on specific mutation**
- **If no cancer history can replace hormones with estrogen until approximate age of natural menopause**

# Risk Reduction for Gynecologic Cancer





# Conclusion

- **All abnormal symptoms need to be investigated b/c of increased risk of EC/OC**
- **No documented benefit of routine surveillance for women with LS**
- **Good evidence that risk-reducing surgery (removal of ovaries and uterus) will prevent cancer**
- **Surveillance only as a temporary measure for those who have not completed child-bearing**
- **Hormone replacement can be given after risk-reducing surgery**